Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6692735

Title:Variant of C6 .beta.-chemokine leukotactin-1(shLkn-1) with enhanced biological activity
Inventors:Kwon, Byoung S.; Carmel, IN, USA
Youn, Byung S.; Seoul, Republic of Korea Chung, Soo-Il; Kyounggi-do, Republic of Korea Park, Doo-Hong; Seoul, Republic of Korea Baek, Seung Jae; Kyounggi-do, Republic of Korea Lee, Eun-Kyoung; Seoul, Republic of Korea Ahn, Ju-Hyung; Kyounggi-do, Republic of Korea Lee, Kong-Ju; Kyounggi-do, Republic of Korea
Summary:This invention describes recombinant shLkn-1 characterized by enhanced biological activity. The invention relates to a truncated variant of the C6 ?-chemokine leukotactin-1 polypeptide consisting of the amino acid sequence of SEQ ID NO:2, as well as a process for preparing a recombinant shLkn-1 employing the expression vector and a pharmaceutical application of the protein. Further disclosed are methods by which shLkn-1 is generated by the missing 26 amino acid residues from the amino terminus of Lkn-1 to contain 66 amino acids. Claims of the invention describe recombinant shLkn-1 as inhibiting colony formation and cell proliferation in vivo, therefore suggesting it as a potential drug for antibody production such as in the treatment of HIV-1 infection, the protection of bone marrow stem cells during chemotherapy or radiotherapy, and in the inhibition of leukemia.
Abstract:The present invention relates to a variant of Lkn-1(shLkn-1) with enhanced biological activity, which is a truncated form of Lkn-1, a process for preparing a recombinant shLkn-1 by employing expression vector therefor and pharmaceutical application of the said protein. shLkn-1 is generated by missing 26 amino acid residues from the amino terminus of Lkn-1 to contain 66 amino acids. Recombinant shLkn-1 inhibits colony formation and cell proliferation in vivo, which suggests that it can be used as a potential drug for the antibody production, the treatment during HIV-1 infection, the protection of bone marrow stem cells during chemotherapy or radiotherapy, and the inhibition of leukemia.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6692735
Application Number:US1999000355193
Date Filed:21/07/1999
Date Published:17/02/2004
Assignee:Korea Green Cross Corporation, Kyounggi-do, Republic of Korea Mogam Biotechnology Research Institute, Kyounggi-do, Republic of Korea


 
Copyright © 2007 The Institute for Cellular Medicine  6/18/2021